Blood Urea Nitrogen-to-Albumin Ratio Predicts 28-Day Mortality in ICU Patients with CKD: Study
Researchers have found in a new study that Blood Urea Nitrogen-to-Albumin Ratio (BAR) shows a significant association with 28-day mortality risk in ICU patients suffering from chronic kidney disease (CKD), highlighting its potential as a valuable tool for mortality risk stratification.
Chronic kidney disease (CKD) is prevalent worldwide, with patients facing significant mortality risk in intensive care units (ICUs). Early identification of high-risk CKD patients is crucial for improving clinical outcomes. The blood urea nitrogen to albumin ratio (BAR) is a simple and measurable indicator, but its relationship with 28-day mortality in CKD patients is not well established. This study aimed to investigate this association.
They conducted a retrospective analysis of eligible CKD patients from the MIMIC IV database. The association between the BAR and 28-day mortality was assessed using Kaplan-Meier survival curves, multivariable Cox regression models, and restricted cubic spline models. Results: A total of 4,625 patients were included, with a 28-day mortality rate of 25.2%. Kaplan-Meier survival curve analysis indicated that patients in the high BAR tertile had significantly lower survival probabilities than those in the low BAR tertile.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.